Moreover, the combination of palbociclib and binimetinib (targeting CDK4/6 and MEK, respectively) was shown to induce tumor cell senescence and matrix remodeling leading to enhanced drug delivery and T-cell infiltration, supporting further study of the combination. Here, MAP2K7 is linked to neoplasm.